This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lecomte, T. Articles by Loriot, M.-A. Search for Related Content PubMed PubMed Citation Articles by Lecomte, T. Articles by Loriot, M.-A.

Glutathione S-Transferase P1 Polymorphism (Ile¹⁰⁵Val) Predicts Cumulative Neuropathy in Patients Receiving Oxaliplatin-Based Chemotherapy

Authors' Affiliations: Departments of ¹ Gastroenterology and ² Biochemistry, Assistance Publique-Hôpitaux de Paris, European Georges Pompidou Hospital; and ³ Université Paris-Descartes, Faculté de Médecine, Institut National de la Sante et de la Recherche Medicale UMRS 775, Paris, France

Requests for reprints: Pierre Laurent-Puig, U775 Bases Moléculaires de la Réponse aux Xénobiotiques, 45 rue des Saints Pères, 75006 Paris, France. Phone: 33-1-428-62081; Fax: 33-1-428-62072; E-mail: pierre.laurent-puig{at}biomedicale.univ-paris5.fr.

Purpose: Glutathione S-transferases (GST) are xenobiotic metabolizing enzymes involved in the detoxification of a variety of chemotherapeutic drugs, including platinum derivatives. Genetic polymorphisms of GSTs have been associated with enzyme activity variations. Thus, a study was done to investigate the relationship between GST polymorphisms and oxaliplatin-related cumulative neuropathy in gastrointestinal cancer patients treated with oxaliplatin-based chemotherapy.

Experimental Design: Ninety patients were included. Clinical neurologic evaluation was done at baseline and before each cycle of treatment. We determined genetic variants for GSTP1 exon 5 (Ile¹⁰⁵Val), GSTP1 exon 6 (Ala¹¹⁴Val), GSTM1 (homozygous deletion), and GSTT1 (homozygous deletion). We conducted analyses in a subgroup of 64 patients receiving a minimal cumulative dose of 500 mg/m² of oxaliplatin to examine whether the GST polymorphisms are associated with oxaliplatin-related cumulative neuropathy.

Results: Among patients receiving a minimal cumulative dose of 500 mg/m² of oxaliplatin, 15 patients showed clinically evident oxaliplatin-related cumulative neuropathy scored grade 3 according to an oxaliplatin-specific scale. The oxaliplatin-related cumulative neuropathy scored grade 3 was significantly more frequent in patients homozygous for the GSTP1 ¹⁰⁵Ile allele than in patients homozygous or heterozygous for the GSTP1 ¹⁰⁵Val allele (odds ratio, 5.75; 95% confidence interval, 1.08-30.74; P = 0.02). No association was found with respect to any of the GSTM1, GSTT1, or GSTP1 exon 6 genotypes.

Conclusions: The results of the current study suggest that the ¹⁰⁵Val allele variant of the GSTP1 gene at exon 5 confers a significantly decreased risk of developing severe oxaliplatin-related cumulative neuropathy.

This article has been cited by other articles:

				A. M. Moyer, O. E. Salavaggione, T.-Y. Wu, I. Moon, B. W. Eckloff, M. A.T. Hildebrandt, D. J. Schaid, E. D. Wieben, and R. M. Weinshilboum Glutathione S-Transferase P1: Gene Sequence Variation and Functional Genomic Studies Cancer Res., June 15, 2008; 68(12): 4791 - 4801. [Abstract] [Full Text] [PDF]

				A. Buchard, J. J. Sanchez, K. Dalhoff, and N. Morling Multiplex PCR Detection of GSTM1, GSTT1, and GSTP1 Gene Variants: Simultaneously Detecting GSTM1 and GSTT1 Gene Copy Number and the Allelic Status of the GSTP1 Ile105Val Genetic Variant J. Mol. Diagn., November 1, 2007; 9(5): 612 - 617. [Abstract] [Full Text] [PDF]

				L. Gamelin, O. Capitain, A. Morel, A. Dumont, S. Traore, L. B. Anne, S. Gilles, M. Boisdron-Celle, and E. Gamelin Predictive Factors of Oxaliplatin Neurotoxicity: The Involvement of the Oxalate Outcome Pathway Clin. Cancer Res., November 1, 2007; 13(21): 6359 - 6368. [Abstract] [Full Text] [PDF]

				A. Ruzzo, F. Graziano, F. Loupakis, E. Rulli, E. Canestrari, D. Santini, V. Catalano, R. Ficarelli, P. Maltese, R. Bisonni, et al. Pharmacogenetic Profiling in Patients With Advanced Colorectal Cancer Treated With First-Line FOLFOX-4 Chemotherapy J. Clin. Oncol., April 1, 2007; 25(10): 1247 - 1254. [Abstract] [Full Text] [PDF]

				J. Oldenburg, S. M. Kraggerud, M. Cvancarova, R. A. Lothe, and S. D. Fossa Cisplatin-Induced Long-Term Hearing Impairment Is Associated With Specific Glutathione S-Transferase Genotypes in Testicular Cancer Survivors J. Clin. Oncol., February 20, 2007; 25(6): 708 - 714. [Abstract] [Full Text] [PDF]